PLx Pharma Inc. to Present at Biotech Showcase 2020HomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)PLx Pharma Inc. to Present at Biotech Showcase 2020GlobeNewswireJanuary 7, 2020ReblogShareTweetShareSPARTA, N.J., Jan. 07, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products, VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”™), announced today that Natasha Giordano, President and Chief Executive Officer, and Rita O’Connor, Chief Financial Officer, will present at the Biotech Showcase 2020 as follows: Date: Tuesday, January 14, 2020
Time: 4:30 p.m. Pacific Standard Time
Location: Hilton San Francisco Union Square, San Francisco, CA
Webcast: https://event.webcasts.com/starthere.jsp?ei=1278482&tp_key=654e903f09 The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.plxpharma.com under the News & Events section.About VAZALORE VAZALORE 325 mg is an FDA-approved aspirin product being developed to provide patients with vascular disease and diabetic patients who are candidates for aspirin therapy with more reliable and predictable antiplatelet efficacy as compared to enteric-coated aspirin, while also reducing the adverse gastric events common in an acute setting. PLx is focused on manufacturing, scale-up and label finalization for VAZALORE 325 mg aspirin dosage form and preparing an sNDA for VAZALORE 81 mg maintenance dose form. Our goal is to begin selling both products in the United States towards the end of 2020, subject to approval by the FDA.About PLx Pharma Inc.PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products. The PLxGuard delivery system works by targeting delivery of active pharmaceutical ingredients (API) to various portions of the gastrointestinal (GI) tract. PLx believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce GI side effects—including erosions, ulcers and bleeding—associated with aspirin and ibuprofen, and potentially other drugs.To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.Contact Investor Relations:Lisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793E: lwilson@insitecony.comSource: PLx Pharma Inc.ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextUS gives Iran sanctions waiver for humanitarian tradeThe IndependentOpioid companies say lawyers' fee demand threatens settlement talksReutersTop Marijuana Stocks on the NASDAQ for March 2020InvestopediaIs JNJ Stock A Buy As It Wages Battle Against The New Coronavirus?Investor's Business DailySTERIS (STE) Stock Hits New 52-Week High: What's Driving it?ZacksBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance Video'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatch